Search Results for: First Patient Treated in Mapi
Articles
February 6, 2018
First Patient Treated in Mapi Pharma’s Phase II Clinical Trial February 6, 2018
Mapi Pharma Ltd recently announced that the first patient has been treated with GA Depot in the company’s Phase II...
June 29, 2021
Fulcrum Therapeutics Announces Results from ReDUX4 Trial With Losmapimod in Facioscapulohumeral Muscular Dystrophy Demonstrating Slowed Disease Progression & Improved Function June 29, 2021
Fulcrum Therapeutics, Inc. recently announced results from the company’s Phase 2b trial, ReDUX4, in people with facioscapulohumeral muscular dystrophy (FSHD). Results being presented with….
March 3, 2022
Fulcrum Therapeutics Announces Phase 3 Clinical Trial March 3, 2022
Fulcrum Therapeutics, Inc. recently announced its plans to initiate REACH, a Phase 3 clinical trial of losmapimod in people with...
December 6, 2021
Fulcrum Therapeutics Announces Additional HBG mRNA Induction From Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease & New Preclinical Mechanism Data December 6, 2021
Fulcrum Therapeutics, Inc. recently announced positive results from the 20-mg and 30-mg dose cohorts in healthy adult volunteers in its...
